14-3-3 sigma/Stratifin Antibody (EPR5872)

Produced using Abcam's RabMab® technology. RabMab® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.

14-3-3 proteins are composed of a highly conserved multigene family of small acidic proteins. Responsive to DNA damage, 14-3-3 sigma expression is induced in a p53-dependent manner. 14-3-3 sigma sequesters cyclin B1-CDC2 complex in cytoplasm, and prevents its entry into nucleus resulting in G2/M cell cycle arrest. Furthermore, 14-3-3 sigma can link to CDK2 and CDK4 and block the cell cycle entry. Thus, 14-3-3 sigma acts as a negative regulator of cell cycle progression and is linked to cancer (1). A keratinocyte-releasable form of 14-3-3 sigma is a potent MMP-1-stimulatory factor in dermal fibroblasts. When it is released from keratinocytes, it induces the expression of MMP1, MMP3, MMP8 and MMP24 in fibroblasts through the p38 mitogen-activated protein kinase (MAPK) signaling pathway (2).

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Array NBP1-95907

• 14-3-3 sigma/Stratifin Antibodies
• 14-3-3 sigma/Stratifin ELISA Kits
• 14-3-3 sigma/Stratifin Lysate
• 14-3-3 sigma/Stratifin Proteins